NCCLS eNews - 13 October 2004 (Print All Articles)Back to Graphical Version | Search back issues Glen A. Fine Named New Executive Vice President of NCCLS/Clinical and Laboratory Standards Institute
Wayne, PA – Dr. Thomas L. Hearn, NCCLS President, has announced the appointment of Glen A. Fine, M.T.(ASCP), M.S., M.B.A, as the organization’s next Executive Vice President, succeeding John V. Bergen, Ph.D. Mr. Fine will join NCCLS on 1 November. Mr. Fine is currently Vice President, Ethics, Regulatory Compliance, and Privacy, for MDS Laboratories, U.S., Inc. in Brentwood, TN. He previously served as the Vice President, Operations for MDS; as General Manager of MDS Hudson Valley Laboratories; as Administrative Director, Laboratory at Paoli Memorial Hospital in Paoli, Pennsylvania; and as Assistant Administrator of the Hospital of the University of Pennsylvania. Mr. Fine’s educational background includes a Master of Business Administration degree in Health Care Administration from St. Joseph’s University and a Master of Science in Clinical Laboratory Sciences from Temple University, Philadelphia, PA. As Executive Vice President and chief staff officer, Mr. Fine will have overall responsibility for the strategic, programmatic, administrative, marketing, and financial management operations of the organization; for communicating the organization’s vision and objectives to its internal and external constituencies; and for providing leadership to the Board of Directors and staff in formulating policy, developing strategy, and implementing programs. Mr. Fine takes on this NCCLS leadership role at an exciting time in its history. On 1 January 2005, NCCLS will officially change its name, becoming the Clinical and Laboratory Standards Institute (CLSI). The new name best reflects the organization’s mission to the healthcare community, depth and breadth of standards-development activities, and global membership base. Commenting on his new role, Mr. Fine said “I am very excited to join NCCLS, an organization which enjoys an outstanding reputation for quality in all of its products and services. With the upcoming name change to CLSI, to reflect an ambitious growth agenda beyond its traditional boundaries, I am delighted to be part of the organization at such an exciting time in its history.” Selection of Mr. Fine, from among many highly qualified candidates, successfully completes a year-long search. The Search Committee was chaired by Dr. Hearn (Centers for Disease Control and Prevention). The committee’s members included Dr. Donna M. Meyer (CHRISTUS Health), Immediate Past President; Wayne Brinster (BD) and Dr. Mary Lou Gantzer (Dade Behring), both members of the Board of Directors; and James A. Thomas, President of ASTM International. According to Dr. Hearn, “Mr. Fine and NCCLS is a very good match! Mr. Fine’s experience in management, marketing, and finance, and his results-oriented approach and style bode well for NCCLS. I am confident that with his leadership NCCLS will become even more prominent as the world’s finest clinical and laboratory standards-development organization. NCCLS has had tremendous growth, masterfully guided by Dr. John Bergen, NCCLS’s outgoing Executive Vice President. I know Mr. Fine welcomes the challenges in moving NCCLS to even higher levels.” Dr. Bergen, who has served as Executive Director and, more recently, Executive Vice President, will retire on 31 December, after 23 years of outstanding service. For additional information on NCCLS or for further information regarding this release, visit our Website at http://www.nccls.org or call +610.688.0100. Press Releases
NCCLS Announces Availability of New Guideline on Evaluation of Precision Performance of Quantitative Measurement Methods This document, Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline–Second Edition (EP5-A2), provides guidance and procedures for evaluating the precision of in vitro diagnostics devices and includes recommendations for manufacturers in evaluating their devices and methods when establishing performance claims. Included are guidelines for the duration, procedures, materials, data summaries, and interpretation techniques that are adaptable for the widest possible range of analytes and device complexity. Read the complete press release. NCCLS Announces Availability of New Guideline on Application of a Quality System Model for Inpatient Medication Use This document, Application of a Quality System Model for Inpatient Medication Use; Approved Guideline (HS10-A), provides the necessary background information and infrastructure to develop a quality system that will meet healthcare quality objectives and be consistent with the quality objectives of each institution. This guideline provides a structure for a comprehensive, systematic approach to build quality into the pharmacy service’s processes, assess its performance, and implement quality improvements. Read the complete press release. NCCLS Announces Availability of New Guideline on Fluorescence Calibration and Quantitative Measurement of Fluorescence Intensity This document, Fluorescence Calibration and Quantitative Measurement of Fluorescence Intensity; Approved Guideline (I/LA24-A), describes the basic principles, reference materials, and laboratory procedures upon which quantitative fluorescence calibration is based. Read the complete press release. NCCLS Announces Availability of New Guideline on Proficiency Testing for Molecular Methods This document, Proficiency Testing for Molecular Methods; Proposed Guideline (MM14-P), is to complement currently available regulatory and guidance documents regarding the management and operations of proficiency testing programs. It will also serve clinical laboratories with a benchmark for evaluation of new programs or, taken in principle, to guide their own program development when necessary. Specific sections discuss the design of materials, assignment of target result, distribution, receipt and evaluation of data, and reporting responsibilities. Read the complete press release. View the complete listing of NCCLS press releases. Notice of Vote and Comment Deadline for Consensus Documents(H54-P) Calibration of PT/INR Systems NCCLS announces that the following documents are submitted for vote as candidate-for-advancement consensus documents. The documents and ballots are posted on NCCLS Forums to delegates of Active and Associate Active member organizations. If you are a voting delegate or alternate, we request that you access NCCLS Forums to obtain the candidate-for-advancement document. Login to access NCCLS Forums. The deadline for the completed ballot for H54-P to be received in the Executive Offices is 11 January 2005. H54-P—Procedures for Validation of INR and Local Calibration of PT/INR Systems; Proposed Guideline -Second Notice- The deadline for the completed ballot for HS3-A to be received in the Executive Offices is 8 November 2004. HS3-A—Pulse Oximetry; Approved Guideline The deadline for the completed ballot for MM14-P to be received in the Executive Offices is 8 December 2004. MM14-P—Proficiency Testing for Molecular Methods; Proposed Guideline Under our Administrative Procedures, an NCCLS document approved by the area committee at the first level of the consensus process is submitted to the NCCLS delegates as a “candidate-for-advancement” consensus document. This begins the voting and approval period by the delegates. As a delegate, your vote is to affirm (or reject) the document for advancement as an NCCLS document. Please send your completed ballot to the Executive Offices by the above deadline. In the NCCLS consensus process, comments are invited at each publication stage. In each edition, the responsible committee includes a summary of comments on the prior edition and its responses to them. Any comments received on a candidate-for-advancement consensus document as a result of delegate voting and consensus review will be addressed by the committee during the document’s advancement. For more information on Active and Associate Active membership, click here. Recently Approved DocumentsFree Hormones (C45-A); Precision (EP5-A2); Arterial Collection (H11-A4); Patient Outcomes (HS6-A); Inpatient Medication Usage (HS10-A); Fluorescence Intensity (I/LA24-A); Cellular Immune Functional Assays (I/LA26-A) NCCLS is pleased to announce that the following documents have been approved by the Board of Directors for publication. See the text following this list for information on options for member and nonmember organizations to obtain copies. C45-A—Measurement of Free Thyroid Hormones; Approved Guideline HS6-A—Studies to Evaluate Patient Outcomes; Approved Guideline -Second Notice- EP5-A2—Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline—Second Edition H11-A4—Procedures for the Collection of Arterial Blood Specimens; Approved Standard—Fourth Edition HS10-A—Application of a Quality System Model for Inpatient Medication Use; Approved Guideline I/LA24-A—Fluorescence Calibration and Quantitative Measurement of Fluorescence Intensity; Approved Guideline I/LA26-A— Performance of Single Cell Immune Response Assays; Approved Guideline The NCCLS procedures have been designed to ensure that consensus has been achieved when a standard or guideline is published at the approved level. This means that a document has been rigorously reviewed by the authoring subcommittee, the area committee overseeing the project, the Board of Directors, and the medical-testing community which participates in the consensus process by carefully reviewing and commenting on the standard or guideline. The listed approved consensus documents are available for purchase. You may automatically receive or select approved-level documents as a member benefit. For information on joining NCCLS, and viewing membership options and benefits, click here. For more information or to contact us directly, please visit nccls.org | © NCCLS, 2003 – All rights reserved |